Agenus EBITDA Margin 2010-2022 | AGEN
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Agenus (AGEN) over the last 10 years. The current EBITDA margin for Agenus as of March 31, 2022 is .
| Agenus EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2022-03-31 |
$0.31B |
$0.04B |
12.26% |
| 2021-12-31 |
$0.30B |
$0.03B |
10.81% |
| 2021-09-30 |
$0.31B |
$0.06B |
20.85% |
| 2021-06-30 |
$0.07B |
$-0.16B |
-228.99% |
| 2021-03-31 |
$0.09B |
$-0.12B |
-145.88% |
| 2020-12-31 |
$0.09B |
$-0.11B |
-125.00% |
| 2020-09-30 |
$0.09B |
$-0.11B |
-117.39% |
| 2020-06-30 |
$0.10B |
$-0.11B |
-112.37% |
| 2020-03-31 |
$0.09B |
$-0.12B |
-136.05% |
| 2019-12-31 |
$0.15B |
$-0.06B |
-41.72% |
| 2019-09-30 |
$0.12B |
$-0.08B |
-68.03% |
| 2019-06-30 |
$0.12B |
$-0.07B |
-63.48% |
| 2019-03-31 |
$0.12B |
$-0.05B |
-42.61% |
| 2018-12-31 |
$0.04B |
$-0.12B |
-316.22% |
| 2018-09-30 |
$0.04B |
$-0.11B |
-276.92% |
| 2018-06-30 |
$0.03B |
$-0.11B |
-393.10% |
| 2018-03-31 |
$0.02B |
$-0.13B |
-741.18% |
| 2017-12-31 |
$0.04B |
$-0.10B |
-233.33% |
| 2017-09-30 |
$0.04B |
$-0.09B |
-217.50% |
| 2017-06-30 |
$0.04B |
$-0.09B |
-224.39% |
| 2017-03-31 |
$0.04B |
$-0.09B |
-197.73% |
| 2016-12-31 |
$0.02B |
$-0.10B |
-443.48% |
| 2016-09-30 |
$0.03B |
$-0.10B |
-408.00% |
| 2016-06-30 |
$0.03B |
$-0.08B |
-278.57% |
| 2016-03-31 |
$0.03B |
$-0.09B |
-329.63% |
| 2015-12-31 |
$0.03B |
$-0.08B |
-320.00% |
| 2015-09-30 |
$0.02B |
$-0.08B |
-415.79% |
| 2015-06-30 |
$0.01B |
$-0.08B |
-535.71% |
| 2015-03-31 |
$0.01B |
$-0.05B |
-454.55% |
| 2014-12-31 |
$0.01B |
$-0.04B |
-525.00% |
| 2014-09-30 |
$0.01B |
$-0.03B |
-516.67% |
| 2014-06-30 |
$0.01B |
$-0.03B |
-620.00% |
| 2014-03-31 |
$0.00B |
$-0.03B |
-1000.00% |
| 2013-12-31 |
$0.00B |
$-0.02B |
-800.00% |
| 2013-09-30 |
$0.00B |
$-0.02B |
-550.00% |
| 2013-06-30 |
$0.00B |
$-0.02B |
-475.00% |
| 2013-03-31 |
$0.00B |
$-0.02B |
-425.00% |
| 2012-12-31 |
$0.02B |
$-0.01B |
-31.25% |
| 2012-09-30 |
$0.02B |
$-0.01B |
-31.25% |
| 2012-06-30 |
$0.02B |
$-0.01B |
-31.25% |
| 2012-03-31 |
$0.02B |
$-0.00B |
-25.00% |
| 2011-12-31 |
$0.00B |
$-0.02B |
-400.00% |
| 2011-09-30 |
$0.00B |
$-0.02B |
-400.00% |
| 2011-06-30 |
$0.00B |
$-0.02B |
-400.00% |
| 2011-03-31 |
$0.00B |
$-0.02B |
-400.00% |
| 2010-12-31 |
$0.00B |
$-0.02B |
-450.00% |
| 2010-09-30 |
$0.00B |
$-0.02B |
-450.00% |
| 2010-06-30 |
$0.00B |
$-0.02B |
-475.00% |
| 2010-03-31 |
$0.00B |
$-0.02B |
-550.00% |
| 2009-12-31 |
$0.00B |
$-0.02B |
-575.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.436B |
$0.296B |
|
Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company's product line includes Oncophage vaccine, a patient-specific therapeutic cancer vaccine. The Company is also developing Prophage, patient-specific therapeutic cancer vaccine; QS-21, vaccine adjuvant; and HerpV, a polyvalent off-the-shelf therapeutic heat shock protein-based vaccine for treatment of genital herpes which are all in the clinical testing stages. Agenus Inc. is headquartered in Lexington, Massachusetts.
|
